Multiple Sclerosis: A MEDSCAPECME SPECIAL REPORT

Current Treatments
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX® is identical to that of natural human interferon beta.

COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of Rebif® is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (Rebif®) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Tysabri is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tysabri is used to treat relapsing forms of multiple sclerosis.

Gilenya™ is a new class of medication called a phingosine 1-phosphate receptormodulator, which is thought to act by retaining certain white blood cells (lympohcytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.

Early Symptoms
The most common early symptoms of MS include:
* Tingling * Numbness
* Loss of balance
* Weakness in one or more limbs
* Blurred or double vision

Less common symptoms of MS may include
* Slurred speech
* Sudden onset of paralysis
* Lack of coordination
* Cognitive difficulties

Listed above, the early symptoms. I tend to be a poster child for these. The symptoms that occur later on are too numerous just to list. There will be a link included that will get you to a site where these symptoms are listed and explained. Keep in mind that someone may have some of these or many of these, there is no way to tell.

Multiple sclerosis statistics show that approximately 250,000 to 350,000 people in the United States have been diagnosed with this disease. The life expectancy for people with multiple sclerosis is nearly the same as for those without MS. Because of this, multiple sclerosis statistics place the annual cost of MS in the United States in the billions of dollars. MS is five times more prevalent in temperate climates -- such as those found in the northern United States, Canada, and Europe -- than in tropical regions. Furthermore, the age of 15 seems to be significant in terms of risk for developing the disease. Some studies indicate that a person moving from a high-risk (temperate) to a low-risk (tropical) area before the age of 15 tends to adopt the risk (in this case, low) of the new area and vice versa. Other studies suggest that people moving after age 15 maintain the risk of the area where they grew up.

The National MS Society

Saturday, August 28, 2010

A MEDSCAPECME SPECIAL REPORT

Update in Early Multiple Sclerosis, Volume 1 MedscapeCME
August 2010

INTRODUCTION

Welcome to the free, CME and nurse CE-certified newsletter, "Achieving Comprehensive Care in Multiple Sclerosis" (MS), focused on the most current management strategies for MS. This newsletter delivers a single CME/CE activity with easy-to-navigate links to original expert interviews, articles, case studies, and conference reports, all of which must be read before being eligible to take the post-test.

Contents of This CME Activity
Clinical Focus: How to Choose an Immunomodulator in 2010 and Beyond
How do you determine the appropriate disease-modifying agent for patients who have early MS or relapsing-remitting disease? What should be your criteria for switching or adding therapy?

Conference Summary: Treating the Many Faces of MS: Reflections From CMSC 2010
Is there value in life-coaching, wellness education, and strength and fitness training in MS? Select abstracts from CMSC 2010 on these and on treatment and adherence in early MS are highlighted.

Expert Interview: Tuning in to the Needs of Patients With Early Multiple Sclerosis
Past and current presidents of CMSC, Colleen Harris and Dr. Michael Kaufman, discuss what clinicians should be aware of when caring for patients who have newly diagnosed MS.

Update in Early Multiple Sclerosis, Volume 1 Special Report is supported by an independent educational grant from Acorda.

User Support

Unsubscribe from this MedscapeCME newsletter.
Unsubscribe from all MedscapeCME mailing lists.
I forgot my Username and Password.

This message was sent to: jswdoyle@sbcglobal.net

MedscapeCME
Member Services
370 Seventh Avenue
New York, NY 10001

No comments:

Subscribe to: Post Comments (Atom)